MY163136A - Peptide radiotracer compositions - Google Patents

Peptide radiotracer compositions

Info

Publication number
MY163136A
MY163136A MYPI2013700257A MYPI2013700257A MY163136A MY 163136 A MY163136 A MY 163136A MY PI2013700257 A MYPI2013700257 A MY PI2013700257A MY PI2013700257 A MYPI2013700257 A MY PI2013700257A MY 163136 A MY163136 A MY 163136A
Authority
MY
Malaysia
Prior art keywords
compositions
imaging
vivo
binding peptides
methods
Prior art date
Application number
MYPI2013700257A
Other languages
English (en)
Inventor
Peter Brian Iveson
Rajiv Bhalla
Bard Indrevoll
Gareth Getvoldsen
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of MY163136A publication Critical patent/MY163136A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1833Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
MYPI2013700257A 2010-08-18 2011-08-11 Peptide radiotracer compositions MY163136A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1013808.9A GB201013808D0 (en) 2010-08-18 2010-08-18 Peptide radiotracer compositions

Publications (1)

Publication Number Publication Date
MY163136A true MY163136A (en) 2017-08-15

Family

ID=42938098

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013700257A MY163136A (en) 2010-08-18 2011-08-11 Peptide radiotracer compositions

Country Status (19)

Country Link
US (1) US9533059B2 (https=)
EP (1) EP2605802B1 (https=)
JP (1) JP6014592B2 (https=)
KR (1) KR101853993B1 (https=)
CN (1) CN103153350B (https=)
AU (1) AU2011290856B2 (https=)
BR (1) BR112013003469A2 (https=)
CA (1) CA2807491C (https=)
CL (1) CL2013000483A1 (https=)
ES (1) ES2626410T3 (https=)
GB (1) GB201013808D0 (https=)
IL (1) IL224463A (https=)
MX (1) MX348733B (https=)
MY (1) MY163136A (https=)
NZ (1) NZ606466A (https=)
PH (1) PH12013500270A1 (https=)
RU (1) RU2594167C2 (https=)
SG (1) SG187878A1 (https=)
WO (1) WO2012022676A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
GB201209082D0 (en) * 2012-05-24 2012-07-04 Ge Healthcare Ltd Purification method
GB201221266D0 (en) * 2012-11-27 2013-01-09 Ge Healthcare Ltd Aldehyde compositions
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322451D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Purification method and compositions
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US20190151483A1 (en) * 2016-07-25 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of making 18f-labeled precursors and peptides, labeled c-met binding peptides, and methods of use thereof
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
GB2589398B (en) * 2019-06-14 2023-02-15 Edinburgh Molecular Imaging Ltd Compounds and methods of use
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
SE2050387A1 (en) * 2020-04-06 2021-10-07 Pvac Medical Tech Ltd Labelled substance and methods of detection of inflammation and infection using said substance
TW202509086A (zh) * 2021-03-22 2025-03-01 日商肽夢想股份有限公司 c-Met蛋白質結合肽複合物
GB202105950D0 (en) * 2021-04-26 2021-06-09 Ge Healthcare Ltd Analytical HPLC

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
AU2002357388A1 (en) 2001-12-27 2003-07-24 The United States Of America, As Represented By The Department Of Veterans Affairs Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
PT2949658T (pt) * 2003-03-03 2018-10-18 Bracco Suisse Sa Péptidos que ligam especificamente o recetor de hgf (cmet) e utilizações dos mesmos
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
GB0420344D0 (en) * 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
EP2043672A4 (en) * 2006-07-07 2009-10-21 Univ Leland Stanford Junior SELECTIVE INHIBITORS OF CASPASES
GB0615211D0 (en) 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
JP5603074B2 (ja) 2006-09-08 2014-10-08 ピラマル イメージング ソシエテ アノニム 18f標識物質のための化合物と方法
EP2099499A2 (en) 2006-12-13 2009-09-16 GE Healthcare AS Synthesis of a radiofluorinated peptide using microwave activation technology
EP2114464A2 (en) * 2006-12-28 2009-11-11 GE Healthcare AS Radiofluorination methods
MX2009009291A (es) 2007-03-01 2009-12-14 Bayer Schering Pharma Ag Compuestos activos biologicamente marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo.
KR101578225B1 (ko) 2007-05-16 2015-12-17 지이 헬스케어 에이에스 영상화를 위한 표지된 hgf 결합성 펩티드
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0716897D0 (en) 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
GB0803477D0 (en) 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method

Also Published As

Publication number Publication date
CA2807491A1 (en) 2012-02-23
EP2605802B1 (en) 2017-04-26
IL224463A (en) 2016-05-31
US20130149241A1 (en) 2013-06-13
PH12013500270A1 (en) 2013-04-01
US9533059B2 (en) 2017-01-03
KR20130135242A (ko) 2013-12-10
CA2807491C (en) 2019-06-04
CL2013000483A1 (es) 2014-03-07
JP6014592B2 (ja) 2016-10-25
BR112013003469A2 (pt) 2016-06-21
CN103153350A (zh) 2013-06-12
SG187878A1 (en) 2013-03-28
AU2011290856B2 (en) 2014-12-04
RU2013105491A (ru) 2014-09-27
EP2605802A1 (en) 2013-06-26
WO2012022676A1 (en) 2012-02-23
CN103153350B (zh) 2016-06-29
GB201013808D0 (en) 2010-09-29
AU2011290856A1 (en) 2013-03-14
ES2626410T3 (es) 2017-07-25
KR101853993B1 (ko) 2018-05-02
RU2594167C2 (ru) 2016-08-10
MX348733B (es) 2017-06-27
JP2013540702A (ja) 2013-11-07
NZ606466A (en) 2014-11-28
MX2013001939A (es) 2013-03-18

Similar Documents

Publication Publication Date Title
MY163136A (en) Peptide radiotracer compositions
MX2013010012A (es) Analogos de octreotato radiomarcado como trazadores de tomografia por emision de positrones.
MY150757A (en) Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
MX2011010295A (es) Reactivos de radiomarcado y metodos.
DOP2011000046A (es) Daa-piridina como ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes y para el tratamiento farmaceutico
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
BR112016010927A2 (pt) Conjugado de fórmula
GB201103696D0 (en) Technetium labelled peptides
EP2928505A4 (en) POSITRONARY EMITTING RADIONUCLEID MARKED PEPTIDES FOR HUMAN UPAR PET IMAGING
Aranda-Lara et al. Synthesis and evaluation of Lys1 (α, γ-Folate) Lys3 (177Lu-DOTA)-Bombesin (1-14) as a potential theranostic radiopharmaceutical for breast cancer
WO2009052970A3 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
WO2009134405A3 (en) Substrate based pet imaging agents
WO2009025914A3 (en) Radiolabelled fluorobenzamide analogues, their synthesis and use in diagnostic imaging
Aranda-Lara et al. Improved radiopharmaceutical based on 99mTc-Bombesin–folate for breast tumour imaging
MX2010001013A (es) Polisacaridos injertados por poliaminas para preparar composiciones radiofarmaceuticas.
GB201121914D0 (en) Method for patient selection
MX2013003398A (es) Agentes de generacion de imagen de apoptosis con base en peptidos lantibioticos.
WO2012040138A3 (en) Choline analogs as radiotracer
TN2009000233A1 (en) Radiolabelling via fluorination of aziridines
WO2011084585A3 (en) Dihydroethidine analogues and uses thereof
BR112013006498A2 (pt) composto
IN2014DN06805A (https=)
MX2013007188A (es) Simplificacion de proceso para compuesto precursor.
GB0421987D0 (en) Novel technetium and rhenium complexes
Juweid et al. Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma?